Addex Therapeutics Ltd
ADXN
$9.47
$0.010.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1.70K | 62.20K | 127.50K |
| Total Other Revenue | 44.10K | 79.00K | 0.00 | 5.20K | -- |
| Total Revenue | 44.10K | 79.00K | 1.70K | 67.50K | 127.50K |
| Cost of Revenue | 284.20K | 173.60K | 74.40K | 236.40K | 375.20K |
| Gross Profit | -240.10K | -94.60K | -72.70K | -169.00K | -247.80K |
| SG&A Expenses | 648.30K | 579.80K | 434.70K | 550.40K | 746.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 932.60K | 753.40K | 509.20K | 786.80K | 1.12M |
| Operating Income | -888.50K | -674.40K | -507.40K | -719.40K | -994.50K |
| Income Before Tax | -2.37M | -1.64M | -1.35M | -1.77M | -1.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.37M | -1.64M | -1.35M | -1.77M | -1.61M |
| Earnings from Discontinued Operations | 142.70K | -- | -18.10K | -2.80K | 15.85M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.23M | -1.64M | -1.37M | -1.77M | 14.24M |
| EBIT | -888.50K | -674.40K | -507.40K | -719.40K | -994.50K |
| EBITDA | -885.90K | -672.00K | -480.30K | -657.40K | -870.20K |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.02 | 0.14 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.02 | 0.14 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 100.52M | 98.35M | 98.33M | 98.30M | 98.31M |
| Average Diluted Shares Outstanding | 100.52M | 98.35M | 98.33M | 98.30M | 98.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |